HOLON, ISRAEL, October 7, 2016 /PRNewswire/ --
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug
discovery company, today announced that John Hunter, Ph.D., Site Head and Vice
President, Antibody R&D, Compugen USA, Inc., will present data on the Company's
CGEN-15029 novel immune checkpoint program at the 31st Annual
Meeting of the Society for Immunotherapy of Cancer to be held
November 9-13 at the Gaylord National
Hotel & Convention Center in National Harbor, Maryland. The presentation titled
"Computational identification, functional characterization and
antibody blockade of a new immune checkpoint in the TIGIT family of
interacting molecules" is scheduled for Friday, November 11 at 11:45 am ET.
About CGEN-15029
CGEN-15029 is one of the novel B7/CD28-like immune checkpoint
target candidates discovered by Compugen utilizing its predictive
discovery infrastructure. In June
2016, COM701, a high affinity antagonist antibody against
CGEN-15029, was selected as the lead therapeutic candidate for the
program.
About Compugen
Compugen is a leading therapeutic discovery company utilizing
its broadly applicable predictive discovery infrastructure to
identify novel drug targets and develop first-in-class biologics.
The primary focus of the Company's current pipeline is on immune
checkpoint target candidates discovered by the Company, potentially
providing the basis for a next wave of therapeutics for cancer
immunotherapy. Compugen's business model is based on selectively
entering into collaborations for its novel target candidates and
drug product candidates at various stages of research and
development under revenue-sharing agreements. The Company is
headquartered in Israel, with
R&D facilities in Israel and
South San Francisco. At the US facilities, monoclonal antibody
therapeutic candidates are discovered and developed against the
Company's novel target candidates. For additional information,
please visit Compugen's corporate website at
http://www.cgen.com.
Forward-Looking Statement
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by the use of
terminology such as "will," "may," "expects," "anticipates,"
"believes," and "intends," and describe opinions about future
events. These forward-looking statements involve known and unknown
risks and uncertainties that may cause the actual results,
performance or achievements of Compugen to be materially different
from any future results, performance or achievements expressed or
implied by such forward-looking statements. Among these risks:
Compugen's business model is substantially dependent on entering
into collaboration agreements with third parties, and Compugen may
not be successful in generating adequate revenues or
commercializing aspects of its business model. Moreover, the
development and commercialization of therapeutic candidates involve
many inherent risks, including failure to progress to clinical
trials or, if they progress to or enter clinical trials, failure to
receive regulatory approval. These and other factors are more fully
discussed in the "Risk Factors" section of Compugen's most recent
Annual Report on Form 20-F as filed with the Securities and
Exchange Commission as well as other documents that may be
subsequently filed by Compugen from time to time with the
Securities and Exchange Commission. In addition, any
forward-looking statements represent Compugen's views only as of
the date of this release and should not be relied upon as
representing its views as of any subsequent date. Compugen does not
assume any obligation to update any forward-looking statements
unless required by law.
Company contact:
Tsipi Haitovsky
Global Media Liaison
Compugen Ltd.
Email: tsipih@cgen.com
Tel: +972-52-598-9892
SOURCE Compugen Ltd.